Project Grant R21AI186936

Award Date 8/1/24
Completion Date 6/30/26
Dollars Obligated $176K
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60607, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $220,224 to the University of Chicago for computational investigations of HIV-1 assembly, maturation, and uncoating processes. The research aims to advance the mechanistic understanding of these critical viral life cycle stages, which could aid in the design of future antiretroviral therapies that disrupt these...
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded Colorado State University a $340,408 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and validate an assay for precision antiretroviral therapy to combat drug resistance in HIV patients. The key products and services to be delivered under this award include: Improving the throughput and capacity of an existing infectivity assay using proviral constructs with an H2B-mRFP...
This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the dynamics and evolution of HIV Gag and GagPol processing. The $752,745 award aims to use molecular dynamics simulations, single-molecule FRET imaging, and cryo-electron tomography to probe the structure and dynamics of Gag and GagPol that enable ordered processing by the viral...
This federal Project Grant award of $696,828, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to define the structural basis of HIV-1 cap hypermethylation and its linkage to viral post-transcriptional control and modulation of host innate immune signaling. Key objectives include elucidating the role of the HIV-1 Rev/RRE regulatory system in cap hypermethylation, and how...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $617,376 to Emory University to conduct research on the activation and maturation of the HIV-1 protease enzyme. The objective is to elucidate the timing and regulation of protease autoactivation, which is critical for the formation of mature, infectious HIV-1 particles. The research will utilize advanced imaging...
This $760,038 federal Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program. The grant supports research by George Mason University to study the anti-HIV properties of the PSGL-1 protein, a newly identified HIV restriction factor. The research aims to determine the structure-function relationship of the PSGL-1 DR domain and its impact on anti-HIV activity through a combination of...
This Project Grant award, totaling $859,597, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award aims to develop a vaccine that can elicit broadly neutralizing antibodies (bNAbs) against the HIV-1 fusion peptide epitope, a major vulnerable site on the viral envelope protein. The key product being developed is a recombinant fusion immunogen combining the HIV-1 fusion peptide with...
This $653,693 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under CFDA 93.855 Allergy and Infectious Diseases Research, supports structural studies of the HIV-1 virus assembly and maturation process, as well as the mechanism of action of the capsid-targeting compound lenacapavir. Specifically, the award will fund the use of cryo-electron microscopy and tomography techniques to examine the molecular details of the immature and mature HIV capsid...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $847,141 to investigate the role of HIV-1 integrase (IN) in virion morphogenesis and target it with novel allosteric integrase inhibitors. The research aims to delineate the sequence and structural features of viral RNA recognized by HIV-1 IN and determine cryo-EM structures of IN tetramers bound to cognate viral RNA...
This $197,366 five-year Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to advance understanding of how the human immune system naturally restricts a specific subset of HIV known as X4-tropic virus. The research study, conducted by The Washington University in Missouri, will (1) characterize the molecular mechanisms driving the immune-mediated restriction of X4-tropic viral...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) is providing $176,096 to the University of Illinois to develop a computational toolkit for systematically dissecting protein drug resistance mechanisms in the context of HIV antivirals. The goal is to elucidate the mechanisms of HIV drug resistance and establish protocols for manipulating protein interactions and dynamics to counteract resistance. The project aims to design mutations that confer stronger resistance than current variants, as well as introduce additional mutations to existing mutants to neutralize their resistance. The insights from this project are intended to inform the development of next-generation HIV antivirals that can neutralize current resistant strains and minimize the chances of new resistant mutations emerging.

Generated 7/1/25, 2:33 AM